Summary of clinical results

Efficacy and safety of CLEANANCE COMEDOMED+ Intensive anti-blemish care - International observational study
Efficacy and tolerability of CLEANANCE COMEDOMED+ Intensive anti-blemish care prescribed alone, in combination with anti-acne medication or as a relay treatment, in adolescents and adults with mild to moderate acne
International observational study
Population
4230 subjects from 21 different countries, aged 12 to 25, with mild to moderate facial acne (GEA score 1 to 3):
50.6% mixed acne (retentional and inflammatory)
36.2% retentional acne
13.2% inflammatory acne
Application of CLEANANCE COMEDOMED+ Intensive anti-blemish care
2 applications per day on the face for 2 to 3 months
- 46.9% as monotherapy
- 48.3% in combination with medication (zinc gluconate, BPO, azelaic acid, erythromycin, topical isotretinoin, glycolic acid, clindamycin, adapalene, salicylic acid, minocycline, spironolactone)
- 4.8% as relay treatment
Evaluation criteria
- Severity of acne (GEA score = Global Evaluation of Acne)
- Efficacy perceived by investigators
- Quality of life questionnaire (CADI scale 0 to 15)
- Skin tolerance
Results
- Highly significant improvement in acne severity score at follow-up visit (2-3 months): -36.4% (p<0.001, versus Inclusion)

Change in acne severity score (GEA) after 2 to 3 months
** p= Statistically Highly Significant (p<0.001, versus Inclusion)
- Anti-imperfection effect perceived by investigators in over 80% of subjects in each population subgroup at follow-up visit (2-3 months)

Anti-acne efficacy perceived by investigators in each subgroup after 2 to 3 months
- Highly significant improvement in quality of life score at follow-up visit (2-3 months): -44.2% (p<0.001, versus Inclusion)

Evolution of quality of life score after 2 to 3 months
** p= Statistically Highly Significant (p<0.001, versus Inclusion)
- Skin tolerance good to very good for 94.7% of subjects
Conclusion
CLEANANCE COMEDOMED+ Soin intensif anti-imperfections applied twice-daily has demonstrated its anti-acne efficacy and benefits in terms of quality of life in a large international cohort.
Good to very good cutaneous tolerance
More summaries of clinical results
Want to read on?
This access is reserved for professionals, registered on Pierre Fabre For Med.
To access the full content, please register or log in if you already have an account.